{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:24:19Z","timestamp":1787315059365,"version":"build-2736575974"},"reference-count":30,"publisher":"American Society for Microbiology","issue":"12","license":[{"start":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T00:00:00Z","timestamp":1637107200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1128\/ASMCopyrightv2"},{"start":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T00:00:00Z","timestamp":1637107200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100000030","name":"HHS | Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["CDC 09FED07950"],"award-info":[{"award-number":["CDC 09FED07950"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"HHS | National Institutes of Health","doi-asserted-by":"publisher","award":["R01-AI111992"],"award-info":[{"award-number":["R01-AI111992"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"HHS | National Institutes of Health","doi-asserted-by":"publisher","award":["1P30AI094189"],"award-info":[{"award-number":["1P30AI094189"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"HHS | U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["U18-FD004004"],"award-info":[{"award-number":["U18-FD004004"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2021,11,17]]},"abstract":"<jats:p>Rifapentine has facilitated treatment shortening for latent tuberculosis infection (LTBI) in combination with isoniazid once weekly for 3\u2009months (3HP) or daily for 1\u2009month (1HP). Our objective was to determine the optimal rifapentine dose for a 6-week monotherapy regimen (6wP) and predict clinical efficacy.<\/jats:p>","DOI":"10.1128\/aac.01705-21","type":"journal-article","created":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T12:52:42Z","timestamp":1633351962000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":7,"title":["Comparative Efficacy of Rifapentine Alone and in Combination with Isoniazid for Latent Tuberculosis Infection: a Translational Pharmacokinetic-Pharmacodynamic Modeling Study"],"prefix":"10.1128","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0578-6554","authenticated-orcid":true,"given":"Kendra K.","family":"Radtke","sequence":"first","affiliation":[{"name":"University of California, San Francisco, Department of Bioengineering and Therapeutic Sciences, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7664-7287","authenticated-orcid":true,"given":"Jacqueline P.","family":"Ernest","sequence":"additional","affiliation":[{"name":"University of California, San Francisco, Department of Bioengineering and Therapeutic Sciences, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5031-9480","authenticated-orcid":true,"given":"Nan","family":"Zhang","sequence":"additional","affiliation":[{"name":"University of California, San Francisco, Department of Bioengineering and Therapeutic Sciences, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9359-9144","authenticated-orcid":true,"given":"Nicole C.","family":"Ammerman","sequence":"additional","affiliation":[{"name":"Johns Hopkins University, Center for Tuberculosis Research, Baltimore, Maryland, USA"},{"name":"Erasmus MC, University Medical Center Rotterdam, Department of Medical Microbiology and Infectious Diseases, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1440-9889","authenticated-orcid":true,"given":"Eric","family":"Nuermberger","sequence":"additional","affiliation":[{"name":"Johns Hopkins University, Center for Tuberculosis Research, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Belknap","sequence":"additional","affiliation":[{"name":"Denver Health and Hospital Authority, Denver, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanna","family":"Boyd","sequence":"additional","affiliation":[{"name":"Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy R.","family":"Sterling","sequence":"additional","affiliation":[{"name":"Vanderbilt University School of Medicine, Nashville, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3143-5579","authenticated-orcid":true,"given":"Rada M.","family":"Savic","sequence":"additional","affiliation":[{"name":"University of California, San Francisco, Department of Bioengineering and Therapeutic Sciences, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","volume-title":"WHO operational handbook on tuberculosis. Module 1: prevention\u2014tuberculosis preventive treatment.","author":"World Health Organization","year":"2020","unstructured":"World Health Organization. 2020. WHO operational handbook on tuberculosis. Module 1: prevention\u2014tuberculosis preventive treatment. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1806808"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.09-0394"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2017.1366311"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104875"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714283"},{"key":"e_1_3_3_8_2","first-page":"991","article-title":"Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study","volume":"117","author":"Kopanoff DE","year":"1978","unstructured":"Kopanoff DE, Snider DE, Jr, Caras GJ. 1978. Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study. Am Rev Respir Dis 117:991\u20131001.","journal-title":"Am Rev Respir Dis"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/145.2_Pt_1.494"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.14.0829"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ323"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8060812"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200905-0795OC"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201103-0397OC"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01918-13"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2013.01.017"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200602-280OC"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.634"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00345-10"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.7.2118-2124.2003"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01533-06"},{"key":"e_1_3_3_22_2","first-page":"1","article-title":"Tubercle bacilli in latent tuberculous lesions and in lung tissue without tuberculous lesions","volume":"4","author":"Opie E","year":"1927","unstructured":"Opie E, Aronson J. 1927. Tubercle bacilli in latent tuberculous lesions and in lung tissue without tuberculous lesions. Arch Pathol Lab Med 4:1\u201321.","journal-title":"Arch Pathol Lab Med"},{"key":"e_1_3_3_23_2","volume-title":"The tubercle bacillus in the pulmonary lesions of man.","author":"Canetti G","year":"1955","unstructured":"Canetti G. 1955. The tubercle bacillus in the pulmonary lesions of man. Springer, New York, NY."},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l5770"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k2738"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-032712-095939"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.11021"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201912-2489OC"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.03940.x"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.7164\/antibiotics.37.1066"},{"key":"e_1_3_3_31_2","volume-title":"Prifitin (rifapentine) product label.","author":"US FDA","year":"2014","unstructured":"US FDA. 2014. Prifitin (rifapentine) product label. US FDA, Silver Spring, MD. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/021024s011lbl.pdf."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01705-21","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01705-21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T18:38:21Z","timestamp":1645468701000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01705-21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,17]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,11,17]]}},"alternative-id":["10.1128\/AAC.01705-21"],"URL":"https:\/\/doi.org\/10.1128\/aac.01705-21","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,17]]},"assertion":[{"value":"2021-08-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01705-21"}}